GANX
Live chart
What they do
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
For information only · Important disclosures
Grades vs sector
No sector grades for GANX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (FY to 2023-12-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Quality & financial health
Piotroski F-score 4/9 · last two fiscal years
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2023 | $55.2K | $-22.3M | $-18.9M |
| 2022 | $140.1K | $-17.6M | $-14.7M |
| 2021 | $165.0K | $-13.9M | $-12.5M |
| 2020 | $28.9K | $-3.6M | $-3.3M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +24.1%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | -0.15 | -0.11 | +26.7% |
| 2026-05-11 | -0.14 | -0.13 | +4.9% |
| 2026-03-26 | -0.14 | -0.11 | +24.1% |
| 2025-11-12 | -0.15 | -0.15 | +2.2% |
| 2025-08-12 | -0.17 | -0.19 | -11.8% |
| 2025-05-14 | -0.17 | -0.16 | +4.0% |
| 2025-03-27 | -0.19 | -0.08 | +57.3% |
| 2024-11-14 | -0.21 | -0.17 | +20.3% |
Stats refreshed 2026-10-21 18:06:15 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026